Post-test: CRC Screening Guidelines Webcast
Answer the 6 multiple choice questions to receive a test score and a link to the program evaluation.
- 1.All of these options for colorectal cancer screening result in approximately equal mortality reduction EXCEPT:
- A.
Fecal immunochemical testing annually
- B.
Colonoscopy every 10 years
- C.
Flexible sigmoidoscopy every 5 years
- D.
Sensitive guiac-based fecal occult blood test every year
- 2.The most important step for the primary care clinician to perform as opposed to the office team is:
- A.
Assess risk for colon cancer
- B.
Recommend to the patient that they be screened for colon cancer
- C.
Remind patients to return the FOBT cards
- D.
Initiate the call to schedule a colonoscopy
- 3.Elements of a high quality colonoscopy-based screening program include all of the following, EXCEPT:
- A.
Use of a patient registry
- B.
Initiation of an Open Access colonoscopy scheduling program
- C.
Initiation of an in-office flexible sigmoidoscopy program
- D.
Use of reminders for patients who were given home stool blood tests
- E.
Development of a single phone call colonoscopy scheduling system
- 4.The individual at highest risk for the development of colon cancer in the next 10 years is:
- A.
A 61-year-old woman who had four hyperplastic polyps removed at colonoscopy 15 months earlier
- B.
A 60-year-old woman who had two 0.4 – 0.6 cm adenomatous polyps removed at colonoscopy 4 months earlier
- C.
A 53-year-old man whose mother was diagnosed with colon cancer at age 71
- D.
A 46-year-old woman with a 19 year history of ulcerative colitis with an intact colon
- 5.All of these approaches are recommended for colon cancer screening by the USPSTF EXCEPT:
- A.
Guiac-FOBT every year
- B.
Fecal Immunochemical Testing (FIT) every year
- C.
Flexible sigmoidscopy every 5 years plus FOBT or FIT every year
- D.
FOBT on a specimen obtained through digital rectal exam every year
- E.
Colonoscopy every 10 years
- 6.Advantages of FIT over guiac FOBT include all of the following, EXCEPT:
- A.
Higher sensitivity
- B.
Improved patient adherence
- C.
Randomized trials evidence of mortality reduction
- D.
No need for dietary modification
- E.
No need to stop non-steroidal anti-inflammatory agents
Back to top